We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01639482
First Posted: July 12, 2012
Last Update Posted: September 16, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Darin Dougherty, Massachusetts General Hospital
July 10, 2012
July 12, 2012
September 16, 2014
April 2010
December 2013   (Final data collection date for primary outcome measure)
rCMRglu [ Time Frame: pre and post-treatment ]
Not Provided
Complete list of historical versions of study NCT01639482 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram
Not Provided
Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET). The following hypothesis will be tested: Antidepressant response or remission in depressed BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed patients.
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with Bipolar Depression
Bipolar Depression
Not Provided
  • Citalopram
  • Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Current age 18-64 years; DSM-IV diagnosis of BPD, type-I, or type-II; Enrolled in the Citalopram Study at Tufts Medical Center

Exclusion Criteria:

  • Current pregnancy, or inability to utilize contraception, The presence of any metallic implants, History of claustrophobia
Sexes Eligible for Study: All
18 Years to 64 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01639482
2009P002712
No
Not Provided
Not Provided
Darin Dougherty, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Not Provided
Massachusetts General Hospital
September 2014